NCT05193981Active, not recruiting
A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
Role of Homocysteine Metabolism, Endothelial Function and Microvascular Rarefaction on Renal Disease Severity and Progression in ADPKD
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to assess homocysteine metabolism and systemic endothelial function at the early stages of the disease and determine the prognostic value of homocysteine, related metabolites, and markers of endothelial function and injury to estimate renal disease severity and progression in patients with early Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 80 (actual)
- First submitted
- 3 Jan 2022
- Start date
- 14 Sept 2021
- Primary completion date
- Dec 2026
- Lead sponsor
- Mayo Clinic
- Diseases
- Polycystic kidney disease
- NCT number
- NCT05193981
What you commit to
- Study type: Observational
- Participants enrolled: 80
- From 14 Sept 2021 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- A concomitant systemic disease affecting the kidney
Other illness
- Diabetes mellitus
Other
- Class 2 according to imaging classification
- Predicted urine protein excretion in urinalysis \>1 g/24 hrs
- Subjects having contraindications to or interference with MRI assessments
- Patients that are part of an interventional study or taking tolvaptan
- Female subjects that are pregnant
Who the study is looking for
- Male and Female subjects, 15-40 years of age, inclusive
- Previous diagnosis of ADPKD (Based on Ravine et al. criteria)
- Class 1 according to imaging classification
- Estimated GFR\>70 mL/min/1.73m\^2(CKD-EPI)
- Ability to provide written, informed consent.
Age in the registry: 15 years to 40 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.